Vitrafy Life Sciences Ltd. has released a press release.
S&P DJI Announces September 2026 Quarterly Rebalance
Earlier from Vitrafy Life Sciences
- Vitrafy enters U.S. Cell & Gene Therapy Market
- FY26 Full Year Results Presentation
- Q4 FY26 Quarterly Activities Report and Appendix 4C
- Vitrafy enters a partnership with Hoxworth Blood Center